184 related articles for article (PubMed ID: 16397163)
1. IV tissue plasminogen activator for stroke in the community: what we know and don't know 10 years after FDA approval.
Furlan AJ
Stroke; 2006 Feb; 37(2):281. PubMed ID: 16397163
[No Abstract] [Full Text] [Related]
2. Thrombolysis in the 3- to 4.5-hour window: what do ECASSkeptics want?
Selim MH; Molina CA
Stroke; 2014 Mar; 45(3):916-7. PubMed ID: 24526059
[No Abstract] [Full Text] [Related]
3. Hyperacute stroke therapy with tissue plasminogen activator.
Alberts MJ
Am J Cardiol; 1997 Aug; 80(4C):29D-34D; discussion 35D-39D. PubMed ID: 9284041
[TBL] [Abstract][Full Text] [Related]
4. IV and IA thrombolytic stroke strategies are complementary.
Donnan GA; Davis SM
Stroke; 2009 Jul; 40(7):2615. PubMed ID: 19443794
[No Abstract] [Full Text] [Related]
5. [Thrombolysis in stroke--results of the ECASS study (European Cooperative Acute Stroke Study)].
Nervenarzt; 1995 Aug; 66(8 Suppl):1-8. PubMed ID: 9131091
[No Abstract] [Full Text] [Related]
6. Intravenous thrombolysis in German stroke units before and after regulatory approval of recombinant tissue plasminogen activator.
Weimar C; Kraywinkel K; Maschke M; Diener HC;
Cerebrovasc Dis; 2006; 22(5-6):429-31. PubMed ID: 16912477
[TBL] [Abstract][Full Text] [Related]
7. The 4.5-hour time window for intravenous thrombolysis with intravenous tissue-type plasminogen activator is not firmly established.
Wechsler LR
Stroke; 2014 Mar; 45(3):914-5. PubMed ID: 24526061
[No Abstract] [Full Text] [Related]
8. Outcomes of Thai patients with acute ischemic stroke after intravenous thrombolysis.
Dharmasaroja PA; Dharmasaroja P; Muengtaweepongsa S
J Neurol Sci; 2011 Jan; 300(1-2):74-7. PubMed ID: 20937509
[TBL] [Abstract][Full Text] [Related]
9. 4.5-hour time window for intravenous thrombolysis with recombinant tissue-type plasminogen activator is established firmly.
Schellinger PD; Köhrmann M
Stroke; 2014 Mar; 45(3):912-3. PubMed ID: 24526060
[No Abstract] [Full Text] [Related]
10. Further randomized controlled trials of tissue plasminogen activator within 3 hours are required.
Lindley RI
Stroke; 2001 Nov; 32(11):2708-9. PubMed ID: 11692040
[No Abstract] [Full Text] [Related]
11. Thrombolysis, community hospitals, and primary stroke center.
Jeng JS
Acta Neurol Taiwan; 2009 Mar; 18(1):1-2. PubMed ID: 19537567
[No Abstract] [Full Text] [Related]
12. Thrombolysis in pediatric stroke study.
Rivkin MJ; deVeber G; Ichord RN; Kirton A; Chan AK; Hovinga CA; Gill JC; Szabo A; Hill MD; Scholz K; Amlie-Lefond C
Stroke; 2015 Mar; 46(3):880-5. PubMed ID: 25613306
[No Abstract] [Full Text] [Related]
13. Is intraarterial tPA within 3 hours the treatment of choice for selected stroke patients?: No.
Lindley RI
Stroke; 2009 Jul; 40(7):2613-4. PubMed ID: 19443793
[No Abstract] [Full Text] [Related]
14. Intraarterial thrombolysis within the first three hours after acute ischemic stroke in selected patients.
Moonis M
Stroke; 2009 Jul; 40(7):2611-2. PubMed ID: 19443796
[No Abstract] [Full Text] [Related]
15. Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign.
Lenzer J
BMJ; 2002 Mar; 324(7339):723-9. PubMed ID: 11909792
[No Abstract] [Full Text] [Related]
16. Changing contraindications for t-PA in acute stroke: review of 20 years since NINDS.
Parker S; Ali Y
Curr Cardiol Rep; 2015 Oct; 17(10):81. PubMed ID: 26277361
[TBL] [Abstract][Full Text] [Related]
17. The results of arterial thrombolysis.
Kroese AJ; Staxrud LE
Ann Chir Gynaecol; 1995; 84(4):350-3. PubMed ID: 8687078
[No Abstract] [Full Text] [Related]
18. Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis.
Maiser SJ; Georgiadis AL; Suri MF; Vazquez G; Lakshminarayan K; Qureshi AI
Int J Stroke; 2011 Feb; 6(1):25-32. PubMed ID: 21205237
[TBL] [Abstract][Full Text] [Related]
19. Intravenous recombinant tissue-type plasminogen activator in the extended time window and the US Food and Drug Administration: confused about the time.
Wechsler LR; Jovin TG
Stroke; 2012 Sep; 43(9):2517-9. PubMed ID: 22910892
[No Abstract] [Full Text] [Related]
20. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke.
Schestatsky P; Picon PD
Neurology; 2005 Dec; 65(11):1844; author reply 1844. PubMed ID: 16344546
[No Abstract] [Full Text] [Related]
[Next] [New Search]
